Definition
Lyme disease is caused by Borrelia burgdorferi, which is transmitted by the bite of the tick species Ixodes scapularis and Ixodes pacificus. Clinical manifestations most often involve the skin, joints, nervous system, and heart. Extracutaneous manifestations are less commonly seen than in earlier years. Early cutaneous infection with B. burgdorferi is called erythema migrans, which is the most common clinical manifestation of Lyme disease. I. scapularis may also be infected with and transmit Anaplasma phagocytophilum (previously referred to as Ehrlichia phagocytophila) and/or Babesia microti, the primary cause of babesiosis. Thus, a bite from an I. scapularis tick may lead to the development of Lyme disease, human granulocytic anaplasmosis (HGA, formerly known as human granulocytic ehrlichiosis), or babesiosis as a single infection or, less frequently, as a coinfection.
Diagnosis
Diagnosis is predicated upon clinical presentation that is consistent with signs and symptoms compatible with the disease and with is supported by a positive serologic/cerebrospinal fluid (CSF) titer by indirect immunofluorescence assay (IFA), Prevue Borrelia burgdorferi antibody detection assay or enzyme-linked immunosorbent assay (ELISA). (Serologic detection of active disease or previous infection involves a 2test approach using a sensitive enzyme immunoassay (EIA) or IFA followed by a Western immunoblot. All specimens positive or equivocal by a sensitive EIA or IFA should be tested by a standardized Western immunoblot) Guideline I. Members with a confirmed Lyme disease diagnosis are eligible for an initial 4-week course of intravenous (IV) antibiotic therapy when the following criteria are met; any: Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure) 96369 Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); initial, up to 1 hour, including pump set-up and establishment of subcutaneous infusion site(s) 96370 Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) 96371 Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); additional pump set-up with establishment of new subcutaneous infusion site(s) (List separately in addition to code for primary procedure) 96374 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug 93675 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) 93676 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure) 99601 Home infusion/specialty drug administration, per visit (up to 2 hours);
99602
Home infusion/specialty drug administration, per visit (up to 2 hours); each additional hour (List separately in addition to code for primary procedure)
